The company will present data at AHA Scientific Sessions 2026 showing its investigational drug ATR 1072 reversed cardiac glycogen accumulation in a PRKAG2 syndrome mouse model, strengthening the rationale for its ongoing Phase 1/2 trial.
The company will present data at AHA Scientific Sessions 2026 showing its investigational drug ATR 1072 reversed cardiac glycogen accumulation in a PRKAG2 syndrome mouse model, strengthening the rationale for its ongoing Phase 1/2 trial.